Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy for Short Cervix - Trial (PREGNANT Short Cervix - Trial)]

Trial Profile

The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy for Short Cervix - Trial (PREGNANT Short Cervix - Trial)]

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Progesterone (Primary)
  • Indications Preterm birth
  • Focus Registrational; Therapeutic Use
  • Acronyms PREGNANT
  • Sponsors Columbia Laboratories; Juniper Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2012 The US FDA has issued a complete response letter to Watson Pharmaceuticals based on the results from this trial.
    • 27 Feb 2012 Additional results from this trial presented in a Watson Pharmaceuticals media release.
    • 14 Dec 2011 Results from a meta-analysis of five clinical trials, including the PREGNANCY trial, published in a Columbia Laboratories media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top